TesamorelinGH-Axis Support for Recomposition
Tesamorelin is a GHRH analog that restores natural, pulsatile growth hormone secretion. Unlike exogenous HGH, it works through your body's own axis—triggering GH release from the pituitary rather than replacing it.
The clinical data is strong: 15–20% visceral fat reduction with lean mass preservation. For people losing weight on GLP-1 agonists and watching strength disappear alongside fat, tesamorelin offers anabolic support during the cut.
| At a Glance | |
|---|---|
| What it is | Synthetic GHRH(1-44) analog |
| Mechanism | Restores pulsatile GH secretion |
| Key outcome | 15–20% VAT reduction + lean mass preservation |
| Dose | 1–2 mg SC, 30–60 min before bed |
| Cycle | 12–16 weeks on, 2–4 weeks off |
| FDA status | Approved for HIV lipodystrophy; off-label for recomp |
Clinical Evidence
| Trial | Population | Duration | Finding |
|---|---|---|---|
| NEJM 2010 | HIV lipodystrophy | 26 wk | 15–20% VAT reduction |
| Lancet HIV 2019 | HIV + NAFLD | 12 mo | Reduced liver fat, slowed fibrosis |
| Metabolism 2014 | Obese adults (non-HIV) | Variable | Improved body composition |
The evidence base is strong. VAT (visceral adipose tissue) drops while lean mass holds. Triglycerides improve. Glucose stays stable.
Why It Matters for GLP-1 Users
GLP-1 agonists drive fat loss but provide no anabolic protection. Studies show 25–40% of weight lost on GLP-1s can be lean mass.
| What GLP-1s Provide | What Tesamorelin Provides |
|---|---|
| Appetite suppression | GH pulsatility restoration |
| Fat loss driver | Lean mass preservation |
| Glucose control | Nitrogen retention during deficit |
GLP-1s create the deficit. Tesamorelin protects what you don't want to lose.
The timing logic: GLP-1 effects peak during waking hours (mobilization, activity). Tesamorelin-driven GH pulses peak during sleep (repair, protein synthesis). Day for breakdown, night for protection.
Dosing
Reconstitution note: Use bacteriostatic water with sodium chloride (isotonic) to reduce injection site sting and prevent welts. Use the reconstitution calculator to determine exact volumes.
| Dose | 1–2 mg |
| Route | Subcutaneous (abdomen or thigh) |
| Timing | 30–60 min before bed, 2+ hours fasted |
| Cycle | 12–16 weeks on, 2–4 weeks off |
Titration:
| Phase | Dose | Duration |
|---|---|---|
| Start | 1 mg nightly | 2–4 weeks |
| Increase | 2 mg nightly | If needed after 2–3 weeks |
| Adjust | EOD dosing | If IGF-1 runs high or side effects |
Week 8 checkpoint: Get IGF-1 labs. Target physiologic elevation (high-normal), not supraphysiologic. If IGF-1 exceeds 350–400 ng/mL, reduce dose.
GLP-1 + Tesamorelin Protocol
GLP-1 agonist: Weekly injection per standard protocol
Tesamorelin: 1–2 mg SC, 30–60 min before bed
Resistance training: 3–4× per week
Protein: 1.6–2.2 g/kg body weightThe GLP-1 handles appetite. Tesamorelin handles hormonal support. Training provides stimulus. Protein provides building blocks.
Side Effects and Safety
Metabolic notes:
- IGF-1 elevation: Expected—this is the mechanism working
- Glucose: Small shifts possible; monitor if diabetic
- Lipids: Generally improve
| Effect | Notes |
|---|---|
| Edema (fluid retention) | Most common. Dose-related, reversible |
| Tingling/numbness | Carpal-tunnel-like. Resolves with dose reduction |
| Injection site reactions | See detailed section below |
| Joint/muscle aches | Usually transient |
Injection Site Reactions: What to Expect
Tesamorelin injection site reactions follow a specific pattern that catches many users off guard: they develop over time, not immediately.
The Histamine Response
Unlike peptides that burn due to pH (like NAD+), tesamorelin triggers a histamine-mediated reaction. The peptide activates mast cells in subcutaneous tissue, releasing histamine that causes:
- Itchy, raised welts ("mosquito bite" appearance)
- Localized redness and warmth
- Mild swelling around the injection site
This is an immune response, not an allergic reaction. It's dose-related and site-dependent.
Progressive Sensitization Timeline
Most users report no issues initially, then progressive reactions:
| Timeframe | Typical Experience |
|---|---|
| Weeks 1–3 | Minimal or no reaction. Users assume they're "fine" |
| Weeks 4–5 | First noticeable welts appear. Often dismissed as technique |
| Weeks 6–8 | Reactions become consistent. Some sites worse than others |
| Weeks 8+ | Pattern stabilizes. Mitigation strategies become necessary |
This progressive onset is why "rotate sites" advice feels inadequate — you rotated from the start, but reactions appeared anyway. The tissue is sensitizing to repeated tesamorelin exposure, not to injection trauma.
Mitigation Strategies
1. Pre-dose antihistamines
Taking an H1 blocker 30–60 minutes before injection reduces histamine response:
- Cetirizine (Zyrtec) 10mg — non-drowsy, long-acting
- Loratadine (Claritin) 10mg — alternative if cetirizine causes drowsiness
- Diphenhydramine (Benadryl) 25mg — stronger but sedating; use if injecting before bed anyway
Most users find antihistamines reduce reaction severity by 50–70%. Some eliminate welts entirely.
2. Deeper injection technique
Shallow SubQ (just under the skin) puts tesamorelin in close contact with mast cell-rich tissue. Deeper injection reduces this:
- Use a ½" needle and inject at 90° angle
- Pinch skin firmly to create depth
- Aim for the fat pad, not just subcutaneous space
- Some users switch to IM (outer thigh) if SubQ reactions persist
3. Site selection
Not all sites react equally. Based on r/Peptides reports:
| Site | Reaction Severity | Notes |
|---|---|---|
| Lower abdomen | Higher | Dense mast cell population |
| Upper abdomen | Moderate | Better than lower |
| Love handles | Lower | Often the best-tolerated site |
| Outer thigh | Variable | Some users tolerate well; others worse |
Find your least-reactive zone and rotate within it rather than across your whole body.
4. Adding extra BAC water
Diluting the injection volume reduces local concentration. If you're using 1mL per dose, try 1.5–2mL. The larger volume spreads tesamorelin across more tissue, reducing the histamine trigger at any single point.
5. Slow injection speed
Rapid injection creates a bolus that triggers stronger mast cell activation. Inject over 30–60 seconds instead of 5–10 seconds.
When Reactions Are Concerning
Typical tesamorelin reactions are localized and resolve within 1–2 hours. Seek medical attention if:
- Welts spread beyond the injection site
- You develop hives on other body areas
- Facial swelling, throat tightness, or difficulty breathing (anaphylaxis — rare but serious)
- Reactions intensify significantly week-over-week despite mitigation
- Injection sites become hard, hot, or develop pus (infection, not histamine)
If you're experiencing severe reactions that don't respond to antihistamines and technique changes, discuss with your provider. Some individuals are simply sensitive to tesamorelin and may need to discontinue or try alternative GHRH analogs.
Monitoring
| Timepoint | Tests |
|---|---|
| Baseline | IGF-1, fasting glucose, HbA1c, lipids |
| Week 8 | IGF-1 (critical decision point) |
| Ongoing | Symptoms; glucose if at-risk |
Who Should Consider Tesamorelin
Good candidates:
- Training adults with central adiposity
- GLP-1 users concerned about muscle loss
- Those with documented NAFLD
- Willing to work with provider and do bloodwork
Not good candidates:
- Active cancer (IGF-1 contraindicated)
- Uncontrolled diabetes
- Those seeking quick fix without training foundation
- WADA athletes (prohibited)
Tesamorelin vs HGH
| Factor | Tesamorelin | Exogenous HGH |
|---|---|---|
| Mechanism | Stimulates your own GH | Replaces with synthetic |
| Pulsatility | Preserved | Flat-line |
| Shutdown risk | Low | Higher |
| Side effect profile | Cleaner | More |
Tesamorelin works with your body's systems rather than bypassing them.
FAQ
Is tesamorelin the same as HGH?
No. Tesamorelin stimulates your pituitary to release its own GH in natural pulses. HGH replaces your production with synthetic hormone.
How long to see results?
Sleep quality improves in 1–2 weeks. Strength stabilizes by weeks 3–6. Body composition changes consolidate by week 8–12.
Can you take it with semaglutide?
Yes. They work on different axes and are complementary. GLP-1 drives fat loss; tesamorelin provides anabolic support.
What time of day?
30–60 min before bed, at least 2 hours after eating. Aligns with natural nocturnal GH secretion.
What are the side effects of tesamorelin?
The most common side effect is fluid retention (edema), which is dose-related and reversible. Some people experience tingling or numbness in the hands (carpal tunnel-like symptoms)—reducing the dose usually resolves this. Injection site reactions are common and often develop progressively over weeks 4–8; see the detailed injection reactions section for mitigation strategies. Joint and muscle aches are usually transient in the first weeks. Serious side effects are rare at physiologic doses.
How do I dose tesamorelin?
Start at 1mg subcutaneously nightly, 30–60 minutes before bed, at least 2 hours fasted. After 2–3 weeks, you can increase to 2mg if needed and tolerated. Check IGF-1 levels at week 8—if they exceed 350–400 ng/mL, reduce the dose or switch to every-other-day dosing. The goal is physiologic elevation, not supraphysiologic levels.
Do I need to cycle tesamorelin?
Yes. Standard protocols run 12–16 weeks on, followed by 2–4 weeks off. Cycling preserves pituitary sensitivity and prevents sustained IGF-1 elevation. Unlike exogenous HGH, tesamorelin works through your own axis, so breaks allow the system to reset naturally. Some practitioners use shorter on-cycles with longer breaks.
What blood tests should I monitor on tesamorelin?
At minimum: IGF-1 at baseline and week 8 (the critical decision point for dose adjustment). Also check fasting glucose, HbA1c, and lipid panel at baseline. If you're at risk for diabetes, monitor glucose more frequently—small shifts are possible. IGF-1 is the key marker: you want it in the high-normal range, not supraphysiologic.
Can tesamorelin help with belly fat?
Yes—this is its primary clinical indication. Studies show 15–20% reduction in visceral adipose tissue (VAT) over 26 weeks. Tesamorelin specifically targets visceral fat, the metabolically dangerous fat around organs, while preserving lean mass. It's FDA-approved for HIV lipodystrophy specifically because of this visceral fat reduction effect.
How do I reconstitute and store tesamorelin?
Reconstitute with bacteriostatic water containing sodium chloride (isotonic) to reduce injection site reactions. Inject water slowly against the vial wall, then gently swirl—don't shake. Store unreconstituted powder refrigerated. Once reconstituted, keep at 2–8°C and use within 28 days. Protect from light. The commercial Egrifta formulation comes with specific diluent and instructions.
Is tesamorelin legal?
Yes, with a prescription. Tesamorelin (brand name Egrifta) is FDA-approved for HIV-associated lipodystrophy. For other uses (recomposition, anti-aging), it's prescribed off-label. It's also available through compounding pharmacies. However, it's prohibited by WADA for competitive athletes. For non-athletes with a prescription, there are no legal restrictions.
Who shouldn't take tesamorelin?
Active cancer or history of cancer is the main contraindication—IGF-1 elevation can promote tumor growth. Uncontrolled diabetes requires caution since GH affects glucose metabolism. Pregnant or nursing women should avoid it. People with pituitary disorders may not respond normally. Anyone unwilling to do bloodwork and work with a provider shouldn't use it—IGF-1 monitoring is essential, not optional.
Tesamorelin for Injury Recovery
Connective tissue doesn't rebuild on your schedule—it rebuilds during sleep. GH pulses during slow-wave sleep trigger IGF-1 production, which drives collagen synthesis and tissue consolidation. When this rhythm is disrupted (from pain, poor sleep, chronic stress, or injury itself), tissue can be structurally repaired but never fully consolidates.
This is the "almost healed, but keeps flaring" pattern. Progress for a few weeks, then mystery regression. The injury site is warm and supple, but strength plateaus 10–15% below baseline. Sleep feels unrefreshed despite adequate hours.
Tesamorelin is a GHRH (Growth Hormone Releasing Hormone) analog that restores nocturnal GH pulsatility—amplifying your body's own sleep-timed repair signals rather than replacing them with exogenous hormone.
| Injury Recovery At a Glance | |
|---|---|
| What it is | Synthetic GHRH(1-44) analog |
| Mechanism | Restores pulsatile, nocturnal GH secretion |
| Primary effect | Sleep-timed tissue repair; IGF-1-driven collagen synthesis |
| Dose | 1–2 mg subcutaneous, 30–60 min before sleep |
| Cycle | 8–12 weeks |
| When to add | Sleep disrupted; recovery unpredictable; strength plateaued despite good structural repair |
Key principle: Tesamorelin is not a healing peptide—it's a timing peptide. It makes existing repair consolidate during sleep instead of oscillating unpredictably.
Who Should Use Tesamorelin for Injury Recovery
Use Tesamorelin If:
- Sleep is choppy, dreams are flat, or you wake unrefreshed
- Recovery feels "random"—good days followed by mystery flares
- Strength has plateaued 10–15% below baseline despite solid rehab
- Structural repair looks good (tissue warm, supple) but consolidation isn't sticking
- You're running a base protocol (BPC-157, TB-500) and need the next layer
Skip Tesamorelin If:
- Tissue is still cold, stiff, or poorly perfused → Need more BPC-157/TB-500
- Energy crashes even at rest → Need NAD+ first
- Pain is clearly structural (not recovery-timing related)
- You haven't tried improving sleep hygiene first
- Active malignancy or proliferative retinopathy (contraindicated)
Do I Need the Base Protocol First?
Recommended but not required. Tesamorelin works best when layered on top of foundational repair:
| Scenario | Recommendation |
|---|---|
| Acute injury (<4 weeks) | Start with BPC-157 + TB-500 |
| Chronic injury with multiple bottlenecks | Start with 5-compound base protocol |
| Sleep/recovery timing is the clear limiter | Tesamorelin can be added earlier |
| Already running base protocol, sleep issues persist | Add Tesamorelin |
Tesamorelin amplifies repair that's already possible. If tissue lacks blood flow (needs BPC-157), cellular mobility (needs TB-500), or energy (needs NAD+), there's less to amplify. But if structural repair is progressing and sleep-timed consolidation is the bottleneck, Tesamorelin addresses that directly.
How Tesamorelin Works for Injury Recovery
The Problem: Disrupted GH Pulsatility
Growth hormone isn't released continuously—it pulses, primarily during slow-wave (deep) sleep. Each pulse triggers hepatic IGF-1 production, which drives:
- Collagen synthesis
- Protein anabolism
- Tissue repair consolidation
When this pulsatile pattern is disrupted (common with chronic pain, poor sleep, stress, or injury), repair becomes unpredictable:
| Normal GH Pattern | Disrupted GH Pattern |
|---|---|
| Strong nocturnal pulses | Flattened, irregular release |
| IGF-1 peaks during sleep | Variable, inconsistent IGF-1 |
| Collagen synthesis overnight | Erratic tissue turnover |
| Predictable recovery | "Two steps forward, one step back" |
What Tesamorelin Does
Tesamorelin is a GHRH analog—it binds pituitary GHRH receptors and triggers your own GH release in natural pulses. Unlike exogenous HGH (which provides constant, flat-line hormone), tesamorelin preserves circadian rhythm and endogenous feedback.
| Pathway | Effect | What You Notice |
|---|---|---|
| Nocturnal GH pulse amplification | Deeper, more consistent GH peaks during slow-wave sleep | More restorative sleep; waking less stiff |
| IGF-1 production | Sustained IGF-1 for tissue synthesis | Tendons and muscles rebuild "overnight" |
| Sleep architecture support | GH pulses reinforce slow-wave sleep | Fewer night wakings |
| Collagen turnover | Organized, predictable remodeling | Progress sticks; fewer mystery flares |
Optional: Adding Ipamorelin
Ipamorelin is a ghrelin receptor agonist that extends the GH pulse window without spiking cortisol. It works synergistically with Tesamorelin:
- Tesamorelin provides the GHRH signal that initiates the GH pulse
- Ipamorelin reduces somatostatin brake and extends pulse duration
| Add Ipamorelin If | Skip Ipamorelin If |
|---|---|
| Tesamorelin alone for 4+ weeks without expected improvement | Tesamorelin is working well |
| Higher-burden recovery (severe injury, high training load) | First cycle; want to assess Tesamorelin response |
| Need extended GH window | Concerned about IGF-1 elevation |
Evidence Note: There are no clinical trials specifically testing Tesamorelin + Ipamorelin for injury recovery. The combination is based on Tesamorelin monotherapy trials, Ipamorelin pharmacology studies, and classical GHRH + GHS synergy physiology. Treat the combination as mechanistically plausible but not directly validated.
Injury Recovery Dosing Protocol
| Compound | Dose | Frequency | Route | Timing | Notes |
|---|---|---|---|---|---|
| Tesamorelin | 1–2 mg | Nightly | SubQ | 30–60 min before sleep | 2+ hours after last meal |
| Ipamorelin (optional) | 200–500 mcg | Nightly | SubQ | With Tesamorelin | Add after 4 weeks if needed |
Titration
| Phase | Dose | Duration |
|---|---|---|
| Start | 1 mg nightly | 2–4 weeks |
| Increase | 1.5–2 mg nightly | If needed after 2–3 weeks |
| Adjust | EOD dosing | If IGF-1 runs high or side effects |
Implementation Notes
- Timing is critical: Inject at least 2 hours after your last meal (carbs and fats blunt GH release)
- 30–60 minutes before sleep is optimal to align with slow-wave stages
- Check IGF-1 at weeks 4 and 8 to keep levels physiologic (high-normal, not supraphysiologic)
- Can co-inject Tesamorelin + Ipamorelin in the same syringe
- Do NOT mix with NAD+ (pH incompatible)
Injury Recovery Timeline
Weeks 1–2
- What's happening: GH timing beginning to consolidate
- What you notice: More restorative sleep; waking less stiff
- Challenge: Stay consistent; effects are subtle at first
Weeks 2–4
- What's happening: IGF-1 production stabilizing; collagen turnover becoming predictable
- What you notice: Fewer "mystery flares" after rehab
- Decision point: If not improving, verify timing and consider adding Ipamorelin
Weeks 4–8
- What's happening: Sleep architecture and nocturnal anabolism stable
- What you notice: Recovery predictable; strength gains stick
- Lab check: IGF-1 at week 4 and 8; adjust dose if supraphysiologic
Weeks 8–12
- What's happening: Tissue consolidation; strength approaching baseline
- What you notice: Progress continues without regression
- Decision point: Continue, taper, or transition to maintenance
Signs Tesamorelin Is Working
- Restorative sleep stable ≥2 weeks
- Waking less stiff; dreams more vivid
- Recovery becomes predictable (fewer mystery flares)
- Strength gains stick after rehab sessions
- No swelling after moderate/heavy sessions
If Issues Persist
If you've optimized GH timing but still experience relapse under load (progress then flare with increased training intensity), consider the SS-31 section for mitochondrial stability.
If neuropathic symptoms persist (burning, tingling, allodynia), consider the ARA-290 section for small-fiber nerve support.
Maintenance Options
After 8–12 weeks:
- Taper off if recovery goals met
- Periodic cycles (4–6 weeks every 6–12 months) for long-term resilience
- Reduced frequency (EOD or 3× weekly) for maintenance
Injury Recovery FAQ
What's the difference between Tesamorelin and HGH for injury recovery?
Tesamorelin stimulates your pituitary to release its own GH in natural, circadian-aligned pulses. HGH replaces your production with synthetic hormone in flat-line, non-pulsatile elevation. For injury recovery, Tesamorelin's preserved pulsatility and circadian alignment make it generally preferred.
How long until I notice something?
Sleep quality often improves in 1–2 weeks. Recovery predictability improves by weeks 3–4. Strength consolidation becomes apparent by weeks 6–8.
Do I need to fast before injection?
Yes. Inject at least 2 hours after your last meal. Carbohydrates and fats blunt GH release, reducing Tesamorelin's effectiveness.
Can I use Tesamorelin without BPC-157/TB-500?
Yes, if sleep timing is your clear bottleneck and structural repair is progressing. Tesamorelin works independently but is often more effective layered on foundational repair.
What if sleep doesn't improve on Tesamorelin?
- Verify timing (30–60 min before sleep, 2+ hours fasted)
- Check sleep hygiene basics (darkness, temperature, consistency)
- Consider adding Ipamorelin
- Rule out other causes (sleep apnea, chronic pain, anxiety)
- Check labs—if IGF-1 isn't rising, reassess source/storage
Can I use Ipamorelin without Tesamorelin?
You can, but they work better together. Tesamorelin provides the GHRH signal that initiates the GH pulse; Ipamorelin extends and amplifies it. Using Ipamorelin alone still produces GH release but without the same circadian synchronization.
Related Topics
- Semaglutide Guide — the GLP-1 benchmark
- Tirzepatide Guide — dual-agonist with better body composition
- AOD-9604 Guide — lipolytic fragment (pairs with tesamorelin)
- GLP-1 Comparison — compare all three
- Retatrutide Guide — triple-agonist investigational
- Retatrutide Recomp Protocol — protecting lean mass
- BPC-157 Guide — Vascular repair layer often used alongside tesamorelin
- TB-500 Guide — Cellular mobility — base repair before GH-axis support
- NAD+ Guide — Cellular energy — distinct from histamine burn mechanism
- Reconstitution Guide — How to prepare tesamorelin with isotonic BAC water
- ARA-290 Guide — For neuropathic symptoms that persist after injury resolution
- SS-31 Guide — Mitochondrial support for load-related relapse
- GLOW & KLOW Protocol — Multi-bottleneck chronic injury protocol
References
- Falutz J, et al. Effects of tesamorelin on body composition in HIV. NEJM 2010.
- Stanley TL, et al. Tesamorelin on hepatic transcriptomic signatures in HIV-NAFLD. Lancet HIV 2019.
- Makimura H, et al. Metabolic effects of GHRH analog in obese adults. Metabolism 2014.
Educational content only. These peptides are not FDA-approved — not because of safety concerns, but because natural peptides cannot be patented, making the billion-dollar clinical trial pathway economically nonviable for any commercial sponsor. This is a structural reality of pharmaceutical economics, not a reflection of safety or efficacy. Work with a qualified healthcare provider before using any peptide protocol.
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.